Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis
Teitsma, Xavier M.; Jacobs, Johannes W.G.; De Jong, Pascal H.P.; Hazes, Johanna M.W.; Weel, Angelique E.A.M.; Welsing, Paco M.J.; Pethö-Schramm, Attila; Borm, Michelle E.A.; Van Laar, Jacob M.; Bijlsma, Johannes W.J.; Lafeber, Floris P.J.G.
(2019) Annals of the Rheumatic Diseases, volume 78, issue 1, pp. 142 - 144
(Letter)
Download/Full Text
The full text of this publication is not available.
Keywords: DMARDs (synthetic), methotrexate, rheumatoid arthritis, Rheumatology, Immunology and Allergy, Immunology, General Biochemistry,Genetics and Molecular Biology, Journal Article
ISSN: 0003-4967
Publisher: BMJ Publishing Group
Note: Funding Information: Competing interests The department of the authors who included patients (JWGJ and JWJB) in the U-Act-Early trial received reimbursements from Roche Nederland BV. JWJB reported grants and fees from Roche, AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer and UCB. JMvL received fees from Arthrogen, MSD, Pfizer, Eli Lilly and BMS and research grants from Astra Zeneca and Roche-Genentech. FPJGL reports grants from Roche. AP-S is an employee of F Hoffmann-La Roche, and MEAB is an employee of Roche Nederland BV. Funding Information: The U-Act-Early trial was funded by Roche Nederland BV and the work within the tREACH trial was supported by an unrestricted grant from Pfizer. Funding Information: Funding The U-Act-Early trial was funded by Roche Nederland BV and the work within the tREACH trial was supported by an unrestricted grant from Pfizer.
(Peer reviewed)